News
Its lead product is NeuroNata-R (lenzumestrocel), the world’s first stem cell-based therapy for amyotrophic lateral sclerosis (ALS). NeuroNata-R was approved as an orphan drug for the treatment ...
It is in late-stage clinical development for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), progressive MS (multiple sclerosis), and DCM (degenerative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback